CMS expands coverage for OPT with verteporfin

Washington, DC-The Centers for Medicare and Medicaid Services (CMS) once again plans to expand its coverage for ocular photodynamic therapy (OPT) with verteporfin (Visudyne, Novartis Ophthalmics).

Related Content:

Practice Management

Managing neovascular retinal disease in COVID-19 era requires careful approach

Moving forward: Does science progress one funeral at a time?

Implementing COVID-19 safety protocols, guidelines in practice